爵士制药 JAZZ 深 沪
已收盘 12-19 16:00:00 美东时间
166.89
+0.890
+0.54%
华盛通- 最 高182.75
- 今 开166.12
- 成交量 75.97万股
- 最 低 161.00
- 昨 收 166.00
- 总市值 104.21亿
- 52周最高 182.99
- 市盈率 静 --
- 换手率 1.22%
- 52周最低 95.49
- 委 比 94.87%
- 总股本 6244.25万
- 历史最高 194.73
- 量 比 0.87
- 振 幅 13.10%
- 历史最低 1.10
- 每 手 1
- 风险率 18.20%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多晚报| 美批准英伟达向中国销售芯片！AI产业链全线爆发！中央城市工作会议：加快构建房地产发展新模式！7月15日影响重磅消息汇总
（来源：京城夜读） 收盘总结 创业板指放量大涨1.73%、沪指险守3500点！两市下跌个股超4000只 AI产业链全线爆发。三大指数全天表现分化，收盘涨跌不一...
07-15 19:43
DraftKings To Rally Over 29%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a comple...
03-11 00:16
Cantor Fitzgerald Reiterates Overweight on Jazz Pharmaceuticals, Maintains $140 Price Target
Cantor Fitzgerald analyst Charles Duncan reiterates Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and maintains $140 price target.
2024-09-09 23:43
Jazz Pharmaceuticals Highlights Zanidatamab and Zepzelca Cancer Trials at ESMO Congress
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the Company, along with its partners, will present five abstracts at the European Society for Medical Oncology (ESMO) Congress 2024 from September 13-17, 2024,
2024-09-09 20:00
Jazz Pharmaceuticals Launches $850 Million Senior Notes Offering, $150 Million Share Buyback
08:03 AM EDT, 09/03/2024 (MT Newswires) -- Jazz Pharmaceuticals (JAZZ) said Tuesday that its subsidiary Jazz Investments I plans to offer $850 million of exchangeable senior notes due 2030 in a private offering. The company said initial purchasers of the notes will be granted a 13-day option to buy ...
2024-09-03 20:03
Jazz Intends To Offer $850M Of Exchangeable Senior Notes Due 2030 In Private Offering; Plans Concurrent Ordinary Share Repurchases Up To $150M Of Its Ordinary Shares
Jazz Pharmaceuticals, together with its consolidated subsidiaries, expects to use a portion of the net proceeds to prepay up to approximately $350 million of the term loans outstanding under the credit agreement and the remainder for general corporate purposes.
2024-09-03 19:02
Jazz And Hikma Accused Of Delaying Sleep Disorder Generic Drug To Maintain High Prices
Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) and Hikma Pharmaceuticals Plc (OTC:HKMPF) (OTC:HKMPY) are set to face allegations that they conspired to delay the release of a generic version of Jazz’s blockbuster narcolepsy drug, Xyrem, resulting in higher prices for health plans. Narcolepsy is a rare, chro...
2024-08-29 01:37
Avadel Pharma Shares Fall After Split Decision in Legal Fight Over Narcolepsy Drug
01:01 PM EDT, 08/28/2024 (MT Newswires) -- Avadel Pharmaceuticals (AVDL) shares declined Wednesday after scoring a partial victory in a legal fight with Jazz Pharmaceuticals (JAZZ) over Avadel's bid to commercialize its Lumryz medication for the treatment of excessive daytime sleepiness in adults wi...
2024-08-29 01:01
'From Five Minutes Of Agony, It's Now Just Seconds,' Says Brazilian Mother Celebrating Free Access To Her Child's Life-Saving CBD Medicine
In 2023, São Paulo enacted a law enabling the dispensing of cannabidiol (CBD)-based medicines across public and private health facilities associated with the Brazilian Unified Health System in Brazil’s most populous state with more than 44 million people. The law made CBD-based medicine accessible a...
2024-08-28 09:11
